An exciting new paper has been published by the team looking at a dashboard of the vital symptoms seen in Parkinson’s Disease: JPM | Free…
Read More
The MDS-ES Neuropsychiatry of Movement Disorders course offers a comprehensive overview into the neuropsychiatryof movement disorders. Recognizing the multiple behavioural domains affected in both hypo- and hyperkinetic…
Research comparing levodopa/carbidopa intestinal gel (LCIG), deep brain stimulation (DBS), and continuous subcutaneous apomorphine infusion (CSAI) for advanced Parkinson’s disease (PD) is lacking. This network…
Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role…
Background. Nonmotor symptoms (NMS) are common in advanced Parkinson’s disease (APD) and reduce health-related quality of life. Objective. The aim of the study was to evaluate…
This is a study sponsored by UCB (a pharmaceutical company) for their new potential medication, UCB0022. This drug works by working on the target sites…
In advanced Parkinson’s disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet…
Continuous drug delivery (CDD) is used in moderately advanced and late-stage Parkinson’s disease (PD) to control motor and non-motor fluctuations (‘OFF’ periods). Transdermal rotigotine is…
Psychiatric-onset prodromal dementia with Lewy bodies (DLBs) is a recently proposed clinical entity characterized by psychiatric presentation that may predate clinical dementia by many years….
Nonmotor symptoms of Parkinson disease are a major factor of disease burden but are often underreported in clinical appointments. A digital tool has been developed…
